The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program.

BACKGROUND & AIMS: Patients with Barrett's esophagus (BE) have a risk of esophageal adenocarcinoma of approximately 0.5% per year. Patients may have difficulty understanding this risk. This study assessed the perceived risk of cancer in patients with BE, and correlated their risk estimates with their health care use behaviors. METHODS: We performed a survey of patients with BE participating in an endoscopic surveillance program at 2 sites: a university teaching hospital and a Veterans' Administration hospital. A questionnaire also elicited their demographics as well as their sources of health information. Health care behaviors, including physician visits and endoscopic surveillance behaviors, were assessed. Patients were classified as either overestimators or nonoverestimators of risk. Characteristics of overestimators, as well as health care use patterns, were assessed. RESULTS: One hundred eighteen patients met entry criteria, and 92 (78%) completed all the questionnaires. Sixty-eight percent of patients overestimated their 1-year risk of cancer, with a mean estimated 1-year cancer risk being 13.6%. The lifetime risk also was overestimated by 38% of patients. Patients who overestimated risk were more likely to be Veterans' Administration medical center patients, have more symptomatic reflux, and were more likely to use the Internet to get health care information. There was no significant difference in physician visits between overestimators and nonestimators (1.2 visits per year vs 1.0, P = .20), nor in endoscopy use (5.7 endoscopies per 5-year period vs 5.0, P = .42). CONCLUSIONS: The majority of patients with prevalent BE participating in an endoscopic surveillance program overestimated their chances of developing adenocarcinoma of the esophagus. Efforts to improve education of such patients with BE are warranted.

Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas.

We did a secondary analysis of data from three large colorectal adenoma chemoprevention trials to assess the association between 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor use and reduced risk of recurrent colorectal adenomas. Reported use of HMG-CoA reductase inhibitors was not associated with a reduced recurrence of colorectal adenomas, multiple adenomas, or advanced adenomas. Lack of statistical power from limited exposure to HMG-CoA reductase inhibitors might be responsible for the lack of association.

Eating frequency and colon cancer risk.

Increased exposure of the colon to bile acids, as a result of increased eating frequency, might promote the development of colon cancer. Our aim was to evaluate the association between eating frequency and colon cancer. We used data from a population-based case-control study of colon cancer in North Carolina. Eating frequency (a combination of meals and snacks) was categorized as fewer than three, three or four, or more than four eating episodes per day. Multivariate logistic regression was used to calculate odds ratios (ORs) for the association between eating frequency and colon cancer, adjusting for confounders. We also performed stratified analyses to evaluate for differences by sex, coffee intake, or tumor site. Six hundred thirty-six participants with colon cancer and 1,048 control participants were included. The effect of eating frequency on colon cancer differed by sex. Among men, participants in the lowest group of eating frequency had approximately half the risk of colon cancer compared with the middle group (adjusted OR = 0.53; 95% confidence interval, CI = 0.30-0.92). Compared with the middle group, men in the highest group had no greater risk of cancer (adjusted OR = 1.03; 95% CI = 0.74-1.44). No significant associations were detected among women. Decreased eating frequency was associated with a lower risk of colon cancer among men but not women.

Digestive and liver diseases statistics, 2004.

BACKGROUND & AIMS: Digestive and liver diseases are associated with substantial morbidity and mortality in the United States. Statistics about the incidence, prevalence, mortality, and resource utilization of digestive and liver diseases in the United States may be cumbersome to obtain because they are scattered in multiple sources. These data may be useful for policy makers, grant applicants, and authors. METHODS: Data on the most common gastrointestinal and liver diseases were collected from large publicly available national databases. Information was collected on inpatient and outpatient gastrointestinal complaints and diagnoses, gastrointestinal cancers, and deaths from common liver diseases. RESULTS: The leading gastrointestinal complaint prompting an outpatient visit is abdominal pain, with 12.2 million annual visits, followed by diarrhea, nausea, and vomiting. Abdominal pain is the leading outpatient gastrointestinal diagnosis, accounting for 5.2 million visits annually, followed by gastroesophageal reflux disease, with 4.5 million visits. Gallstone disease is the most common inpatient diagnosis, with 262,411 hospitalizations and a median inpatient charge of USD$11,584. Colorectal cancer is the most common gastrointestinal cause of death and is the most common gastrointestinal cancer, with an incidence of 54 per 100,000. Among gastrointestinal cancers, primary liver cancer had the highest increase in incidence from 1992 to 2000. CONCLUSIONS: Gastrointestinal and liver diseases are associated with significant outpatient and inpatient healthcare utilization. Following trends in utilization is important for determining allocation of resources for health care and research.

Quality of colon carcinoma pathology reporting: a process of care study.

BACKGROUND: In 1996, the Association of Directors of Anatomic and Surgical Pathology (ADASP) published recommendations for colon carcinoma reporting. Since this publication, no study has evaluated physician practice in relation to these recommendations. The objectives of the current study were to describe pathology reporting for colon carcinoma, evaluate potential variations in reporting, and identify areas for improvement. METHODS: Data were obtained from a population-based study of incident colon carcinoma in 33 counties in North Carolina between 1997 and 2000. All subjects with surgically resected colon carcinoma of tumor stage T2-T4 with available surgical pathology reports were eligible for inclusion in the current analysis. The authors reviewed pathology reports for adherence to recommendations of the ADASP. RESULTS: Four hundred thirty-eight pathology reports were included for analysis. Adherence to ADASP recommendations was < 90% for descriptions of how specimen was received (68%), how specimen was identified (71%), macroscopic depth of penetration (82%), appearance of serosa adjacent to tumor (50%), and status of residual bowel (73%). All other criteria were reported in > 90% of patients. Teaching hospital and contract pathology laboratories had greater adherence to recommendations, compared with community hospital laboratories. Hospitals with the highest colon carcinoma case volume demonstrated greater adherence to recommendations, compared with low-volume hospitals. CONCLUSIONS: Pathology reports were effective in communicating most pertinent findings from surgically resected colon carcinoma specimens. Omissions of some critical characteristics did occur, however, and significant variability in reporting existed based on laboratory affiliation and hospital case volume.

The changing epidemiology of esophageal adenocarcinoma.

The incidence of esophageal adenocarcinoma has risen rapidly over the past 3 decades. This increase had been most dramatic among white men. It has supplanted squamous cell carcinoma as the predominant histologic type of esophageal cancer in the United States. The reasons underlying this phenomenon are not readily apparent. Improvements in diagnostic techniques and changes in cancer classification may explain some of the rise in reported incidence rates, but detection bias and misclassification bias do not appear adequate to explain the increase entirely. Risk factors for esophageal adenocarcinoma are reviewed, with particular emphasis on their role in underlying the rising cancer incidence. The etiologic factors most likely to explain the current epidemic of esophageal adenocarcinoma are the parallel epidemic of obesity, rising use of lower esophageal sphincter-relaxing medications, decreasing Helicobacter pylori infection, changes in the Western diet, and distant smoking habits.